Version July 2025
| Persons who are at risk during an outbreak attributable to a vaccine group | Individuals with exposure to group A, C, W, Y | Individuals with exposure to serogroup B* |
| Healthy persons with no immunizations against meningococcal disease | ||
| 2 months old | 4 doses of MenACWY-CRM, at ages 2-, 4-, 6-, and 12-months | No recommendations |
| 3 through 6 months old | 3 to 4 doses of MenACWY-CRM:
| No recommendations |
| 7 through 23 months old | 2 doses of MenACWY-CRM¶, 12 weeks apart | No recommendations |
| 2 through 9 years old | 1 dose of MenACWY | No recommendations |
| ≥10 years old | 1 dose of MenACWY | 3 doses of either MenB formulation at 0-, 1- to 2-, and 6-months. MenB formulations are not interchangeable. A single manufacturer's MenB products must be used for each dose of the primary series and all booster doses. |
| Patients who have completed an age-appropriate primary series of meningococcal vaccine | ||
| 2 through 6 years old | 1 dose if ≥3 years since last dose of MenACWY vaccine | No recommendations |
| 7 through 9 years old | 1 dose if ≥5 years since last dose of MenACWY vaccine | No recommendations |
| ≥10 years | 1 dose if ≥5 years since last dose of MenACWY vaccine | Unvaccinated patients: 3 doses of either MenB formulation at 0-, 1- to 2-, and 6-months. Previously vaccinated patients: 1 dose if ≥1 year since completing primary MenB vaccine.Δ MenB formulations are not interchangeable. A single manufacturer's MenB products must be used for each dose of the primary series and all booster doses. |
This table is meant for use with UpToDate content related to meningococcal vaccination. Refer to UpToDate content for additional details. Detailed recommendations for outbreak management are available from the CDC. Consult local public health authorities to identify persons who require vaccination.
MenACWY-D (Menactra) was discontinued in 2022.
Although each of the MenACWY vaccine formulations use a different protein conjugate, the products are considered interchangeable in persons ≥2 years of age. The same vaccine product is recommended, but not required, for all doses.
CDC: United States Centers for Disease Control and Prevention; MenACWY: meningococcal groups A, C, W, and Y conjugate vaccine; MenB: serogroup B meningococcal vaccine.
* If the vaccine type of any previous doses received is not known, the primary series should be restarted and completed using either MenB-4C or MenB-FHbp, since the MenB vaccines are not interchangeable.
¶ For children age 7 through 23 months, the second dose of MenACWY-CRM should be ≥12 weeks after the first dose and after the first birthday.
Δ A booster dose interval of ≥6 months may be considered by public health officials to avoid missed opportunities for vaccination. Similarly, if the formulation used for the primary series is unavailable or unknown and cannot be quickly determined, any type of MenB vaccine may be administered. However, if possible, the same formulation of MenB vaccine that was used for the primary series should be used, since there are no data on the efficacy of using a different formulation for the booster dose.
